Madrigal Pharmaceuticals, Inc. MDGL NASDAQ

Madrigal Pharmaceuticals, Inc. (MDGL) reported total assets of $1.26B and total liabilities of $656.9M for fiscal year 2025, resulting in total equity of $602.69M.

The company held $983.56M in cash and short-term investments. Total debt stood at $354.36M, with net debt of $155.67M. The Debt-to-Equity (D/E) ratio was 0.59 (moderate).

Current ratio is 4.01, indicating strong short-term liquidity. Interest coverage is -13.5x (weak).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (67/100) — Total assets $1.26B and equity $602.69M support the company's competitive scale
• VALUE (96/100) — Debt-to-Equity 0.59 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 54/100 with 2/7 criteria passed.

KRYS

Krystal Biotech, Inc.

$270.00

+0.97%

ACLX

Arcellx, Inc.

$114.89

+0.02%

PTCT

PTC Therapeutics, Inc.

$73.01

+3.68%

TGTX

TG Therapeutics, Inc.

$34.56

+2.28%

TERN

Terns Pharmaceuticals, Inc.

$52.68

+0.13%

VKTX

Viking Therapeutics, Inc.

$35.52

+1.46%

SRPT

Sarepta Therapeutics, Inc.

$22.15

+1.65%

DAWN

Day One Biopharmaceuticals, Inc.

$21.46

-0.14%